SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is experiencing a surge in retail interest and social media activity fueled by a 'Save Wendy's' campaign and high short interest that has sparked speculation of a potential short squeeze. Community members are actively debating the company's turnaround potential, the likelihood of a take-private acquisition, and the historical parallels to other high-volatility meme stocks.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir Technologies is facing intense selling pressure as a broader tech-sector reset and macro concerns weigh on investor sentiment, overshadowing recent AI partnership announcements. The community is sharply divided, with bulls pointing to the company's long-term enterprise AI role as a buying opportunity, while bears focus on technical breakdowns and concerns over high valuation multiples.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

The iShares Silver Trust (SLV) is seeing active debate as investors weigh the impact of shifting geopolitical tensions in the Middle East against a hawkish Federal Reserve outlook. Community discussion remains heavily polarized between bulls betting on a supply-demand deficit and long-term industrial necessity, and bears warning that technical support levels are vulnerable to further macroeconomic pressure.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is experiencing intense volatility as investors weigh a strong revenue growth and a high-profile multi-year OpenAI deal against concerns regarding contracting margins and significant upcoming share lockup expirations. The community remains deeply divided, with bulls pointing to the company's technical edge in AI inference and backlog expansion, while bears cite extreme valuation multiples and the potential for heavy selling pressure from insiders.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant attention as investors position themselves ahead of major clinical milestones and potential acquisition interest. The community is actively debating the strategic timing of an equity raise, with many interpreting the move as a sign of financial strength and institutional demand ahead of an anticipated buyout or product launch.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy Inc. is trending as the market anticipates the release of its Q2 earnings, with investors closely watching for updates on the conversion of its massive 4 GW proposal pipeline into firm data center contracts. The stock continues to see high short interest and speculative volatility as the community remains divided between those betting on an upcoming breakout driven by the AI infrastructure narrative and those skeptical of continued dilution and lack of revenue-producing contracts.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is seeing significant momentum as investors rally behind the upcoming launch of Grand Theft Auto VI, with market enthusiasm fueled by reports of imminent pre-order windows and anticipation for new trailers. The community is actively discussing the potential for record-breaking sales and long-term revenue growth from the title, treating the stock as a prime opportunity for institutional positioning ahead of the highly awaited November release.

Hertz Global Holdings, Inc. engages in the vehicle rental business through Hertz, Dollar, and Thrifty brands. It operates through the following business segments: Americas Rental Car (RAC) and International Rental Car (RAC). The Americas RAC segment focuses on operations in the United States, Canada, Latin America, and the Caribbean. The International RAC segment includes the provision of rental and sales of vehicles and value-added services in other locations. The company was founded in 1918 and is headquartered in Estero, FL.

Hertz Global Holdings Inc. - Ordinary Shares (New)

Hertz Global Holdings Inc

Hertz is seeing heightened volatility and investor attention as community members debate the potential for a short squeeze, fueled by significant short interest and recent strategic partnerships within the mobility sector. While some traders are closely watching institutional moves and technical support levels for a potential turnaround, others remain cautious due to historical bankruptcy baggage and ongoing questions regarding the company's long-term profitability.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is seeing heightened investor activity driven by optimism surrounding its VK2735 obesity pipeline and ongoing speculation regarding potential partnerships or a buyout. Community discussions are heavily focused on the company's upcoming Phase 3 maintenance trial data, which is widely viewed as a critical catalyst for validating the drug's long-term commercial potential against established competitors.

Absci Corp. is the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins. It partners with pharma and biotech innovators to create the next generation of protein-based drugs. The company was founded by Sean McClain in 2011 and is headquartered in Vancouver, WA.

Absci Corp

Absci is capturing significant attention as investors react to positive interim Phase 1 data for its novel antibody ABS-201 and a strategic capital raise that brought in top-tier investors. The community is buzzing over the stock's AI-driven drug discovery narrative and potential short-squeeze dynamics, as traders debate whether current momentum can sustain a breakout past key resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Super Micro Computer, Summit Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

US stock futures lower, Nasdaq down 1%. Super Micro shares down 8.6% after announcing $7B offering to fund AI orders. Other stocks also down in pre-market trading.read more...

Why Is SMMT Stock Tumbling Today?

Equity

Summit announced a common stock offering, with underwriters having a 30-day option to purchase up to an additional $75 million of shares.

Summit Therapeutics Announces Proposed Public Offering of Common Stock

Summit Therapeutics Inc. (Nasdaq: SMMT) (Summit, we, or the Company) today announced that it has commenced an underwritten public offering of $500.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Summit. In addition, Summit intends to grant...

Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data

Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data...

Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that it will participate in and present at the 47th Annual Goldman Sachs Global Healthcare Conference in Miami, Florida on Monday, June 8, 2026. Members of the Summit management team will participate in a fireside chat presentation at 10:00 AM...

All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy

Summit Therapeutics (SMMT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors Are Watching This High-Stakes Corner of Biotech

The race to improve therapies is heating up as Wall Street hunts for the next winners. NASDAQ:SPRC, NASDAQ:NTHI, NYSE:JNJ, NASDAQ:SMMT, NASDAQ:BNTX

Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments

Cantor Fitzgerald Maintains Overweight Rating on Summit Therapeutics (SMMT) Amid Mixed Clinical Developments...

What's Going On With Summit Therapeutics Stock On Monday?

Summit Therapeutics' new ivonescimab trial results showed a survival benefit in lung cancer and encouraging data in colorectal cancer.read more...

Wall Street Analysts Think Summit Therapeutics (SMMT) Could Surge 67.1%: Read This Before Placing a Bet

The consensus price target hints at a 67.1% upside potential for Summit Therapeutics (SMMT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$14.25
Prev Close	$14.28
Open	$13.93
Dividend Yield	0.00%
50-Day Moving Average	$17.88
Beta	1.60
Avg. Volume	4.69M
PE Ratio	-8.89

52-Week High	$30.98
52-Week Low	$12.55
Market Capitalization	$11.06B
EPS (Annual)	-$1.44
Price to Book	20.26
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

SMMTSummit Therapeutics Inc

Latest SMMT News